Canaccord analyst William Plovanic raised the firm’s price target on AtriCure (ATRC) to $53 from $51 and keeps a Buy rating on the shares. The firm said they reported a very solid Q2, with strength across the rest of the business more than offsetting further degradation of US EPi-Sense/Hybrid. The target increase reflects comp group multiple expansion and increased expectations.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- Atricure’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- AtriCure’s Strong Q2 2025 Performance and Raised Outlook
- AtriCure reports Q2 adjusted EPS (2c), consensus (16c)
- AtriCure cuts FY25 EPS view to (39c)-(34c) from (55c)-(50c), consensus (51c)
- ATRC Earnings this Week: How Will it Perform?